GSK still a top pick in pharma sector for Deutsche Bank

GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024. “Top-down, our sector view remains neutral and perhaps even more incrementally cautious for 2023 relative to FY23; however we do have a very clear rank order of preferences, with Novo, GSK and Novartis our buy recommendations.” AstraZeneca, Roche and Sanofi are its least preferred options. Deutsche Bank’s target price for GSK rises to 1,850p from 1,7 ...